KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Retained Earnings (2018 - 2025)

Esperion Therapeutics' Retained Earnings history spans 8 years, with the latest figure at -$1.6 billion for Q4 2025.

  • For Q4 2025, Retained Earnings changed N/A year-over-year to -$1.6 billion; the TTM value through Dec 2025 reached -$1.6 billion, changed N/A, while the annual FY2025 figure was -$1.6 billion, N/A changed from the prior year.
  • Retained Earnings reached -$1.6 billion in Q4 2025 per ESPR's latest filing, up from -$1.7 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$93000.0 in Q3 2022 to a low of -$1.7 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$1.2 billion, with a median of -$1.3 billion recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 99.99% in 2022, then crashed 532886.69% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$1.1 billion in 2021, then fell by 21.12% to -$1.3 billion in 2022, then dropped by 4.61% to -$1.4 billion in 2023, then dropped by 12.7% to -$1.6 billion in 2024, then decreased by 2.79% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Retained Earnings are -$1.6 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$1.7 billion (Q2 2025).